Presentation is loading. Please wait.

Presentation is loading. Please wait.

Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple.

Published byElvin Brasington Modified over 9 years ago

Similar presentations

Presentation on theme: "Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple."— Presentation transcript:

1 Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple negative breast cancer (TNBC) – Results from GeparSixto Gunter von Minckwitz, Eric Hahnen, Peter A. Fasching, Jan Hauke, Andreas Schneeweiss, Christoph T. Salat, Mahdi Rezai, Jens U. Blohmer, Dirk M. Zahm, Christian Jackisch, Bernd Gerber, Peter Klare, Sherko Kümmel, Holger Eidtmann, Stephan Paepke, Valentina Nekljudova, Sibylle Loibl, Michael Untch, Rita Schmutzler for the GBG/AGO-B study groups Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

2 Introduction Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

3 Slide 3 Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

4 Slide 4 Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

5 Selected Objectives Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

6 Key Eligibility Criteria Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

7 pCR Rates (ypT0 ypN0) Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

8 Slide 8 Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

9 Characteristics of patients with TNBC Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

10 pCR Rates (%) in Patients with TNBC Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

11 Slide 11 Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

12 pCR (ypT0 ypN0) in all Patients with TNBC Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

13 pCR (ypT0/is ypN0) in all Patients with TNBC Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

14 Prediction of Carboplatin Effect on pCR Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

15 Summary Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

16 Conclusion Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

17 Acknowledgements Presented By Gunter Von Minckwitz at 2014 ASCO Annual Meeting

Download ppt "Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple."

Similar presentations

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Highlights from the San Antonio Breast Cancer.

Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Highlights from the San Antonio Breast Cancer.
Highlights in the management of breast cancer How to improve the outcome of Triple-Negative Breast Cancer Claudia Bighin IRCSS – AOU S. Martino – IST Genova.

Highlights in the management of breast cancer How to improve the outcome of Triple-Negative Breast Cancer Claudia Bighin IRCSS – AOU S. Martino – IST Genova.
The 70-Gene Profile and Chemotherapy Benefit in 1,600 Breast Cancer Patients Bender RA et al. ASCO 2009; Abstract 512. (Oral Presentation)

The 70-Gene Profile and Chemotherapy Benefit in 1,600 Breast Cancer Patients Bender RA et al. ASCO 2009; Abstract 512. (Oral Presentation)
OPEN ISSUES IN MULTIDISCIPLINARY BREAST CANCER MANAGEMENT

OPEN ISSUES IN MULTIDISCIPLINARY BREAST CANCER MANAGEMENT
© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 1 “RDA: better chemotherapy management” Investor Presentation April 2013.

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 1 “RDA: better chemotherapy management” Investor Presentation April 2013.
Presented By Raymond Huang at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting
The phase III ICE study: Adjudiscloseant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer Gunter.

The phase III ICE study: Adjudiscloseant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer Gunter.
CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.
Role of MRI in Breast Cancer Angela Kong Princess Margaret Hospital.

Role of MRI in Breast Cancer Angela Kong Princess Margaret Hospital.
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent.

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.
Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.

Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.
Gunter von Minckwitz, MD, PhD Chairman of German Breast Group Germany

Gunter von Minckwitz, MD, PhD Chairman of German Breast Group Germany
A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.

A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.
The Role of Ultrasound of the Regional Nodal Basins in Staging Patients with Triple Negative Breast Cancer: Implications for Local-Regional Treatment Simona.

The Role of Ultrasound of the Regional Nodal Basins in Staging Patients with Triple Negative Breast Cancer: Implications for Local-Regional Treatment Simona.
Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.

Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.
Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.

Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.
Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.

Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS , ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.
A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.

A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.
Pritchard KI et al. Proc SABCS 2010;Abstract P

Pritchard KI et al. Proc SABCS 2010;Abstract P

Similar presentations

Ads by Google